<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941367</url>
  </required_header>
  <id_info>
    <org_study_id>LPS14410</org_study_id>
    <secondary_id>U1111-1172-3026</secondary_id>
    <nct_id>NCT02941367</nct_id>
  </id_info>
  <brief_title>Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan</brief_title>
  <acronym>LixiRam</acronym>
  <official_title>International, Randomized, Open Label Study to Compare the Safety and Efficacy of Lixisenatide vs. Sulfonylurea on Top of Basal Insulin Treatment in Type 2 Diabetes Mellitus Subjects Who Elect to Fast During Ramadan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To compare the safety, in terms of percentage of patients with symptomatic documented&#xD;
      hypoglycemia during Ramadan fast, of lixisenatide versus sulfonylurea (SU).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess effect of lixisenatide versus SU on:&#xD;
&#xD;
        -  Changes in glycemic control;&#xD;
&#xD;
        -  Changes in body weight.&#xD;
&#xD;
        -  To assess overall safety of lixisenatide and SU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient will have a minimum 12 weeks and maximum 22 weeks (up to&#xD;
      2 weeks screening period + 8-12 weeks pre-Ramadan period + 29-30 days Ramadan + 0 4 weeks&#xD;
      post-Ramadan period). This is a phase 3b study in Kingdom of Saudi Arabia and Bangladesh&#xD;
      (instead of phase 4 for other countries).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Actual">August 4, 2017</completion_date>
  <primary_completion_date type="Actual">August 4, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with at least 1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; 3.9 mmol/L)</measure>
    <time_frame>Approximately 30 days (from start to end of Ramadan holy month)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in HbA1c</measure>
    <time_frame>Baseline, 0-4 weeks pre- and 0-4 weeks post-Ramadan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in body weight</measure>
    <time_frame>Baseline, 0-4 weeks pre- and 0-4 weeks post-Ramadan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with 2-hour post prandial glucose (2hPPG) &lt;180 mg/dL (10 mmol/L)</measure>
    <time_frame>Last 14 days of Ramadan month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HbA1C &lt;7%</measure>
    <time_frame>At 0-4 weeks pre- and 0-4 weeks post-Ramadan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with fasting plasma glucose (FPG) &lt;130 mg/dL (7.22 mmol/L)</measure>
    <time_frame>At pre-Ramadan visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HbA1c &lt;7%, no weight gain and no documented symptomatic hypoglycemia (plasma glucose ≤70 mg/dL; 3.9 mmol/L)</measure>
    <time_frame>At 0-4 weeks pre- and 0-4 weeks post-Ramadan</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lyxumia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide (AVE0010)</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Lyxumia</arm_group_label>
    <other_name>Lyxumia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Sulfonylurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Lyxumia</arm_group_label>
    <arm_group_label>Sulfonylurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basal insulin</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Lyxumia</arm_group_label>
    <arm_group_label>Sulfonylurea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Patients with type 2 diabetes mellitus, diagnosed for at least 1 year at the time of&#xD;
             the screening visit, insufficiently controlled with basal insulin + SU (≤50% max&#xD;
             allowed dose) ±1 oral antidiabetic (OAD) drug.&#xD;
&#xD;
          -  Patients who express the intention to fast during Ramadan.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  At the time of screening age &lt; legal age of majority.&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) at screening visit: &lt;7.5% or &gt;10%.&#xD;
&#xD;
          -  Body mass index (BMI) &lt;20kg/m^2.&#xD;
&#xD;
          -  Treatment with basal insulin for less than 6 months prior to screening.&#xD;
&#xD;
          -  Prior antidiabetic medication (basal insulin and OADs) not at stable dose (eg, same&#xD;
             medication, frequency and &lt;20% dose change) in the last 8 weeks prior to screening.&#xD;
&#xD;
          -  Previous treatment with short or rapid acting insulin other than for short term use&#xD;
             (≤10 days) in relation to hospitalization or an acute illness in the last 6 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Any discontinuation from a glucagon like peptide-1 receptor agonist (GLP-1 RA) due to&#xD;
             safety/tolerability issue or lack of efficacy.&#xD;
&#xD;
          -  Patient not willing to perform self-monitored plasma glucose (SMPG) as required by&#xD;
             protocol and to follow the instructions provided.&#xD;
&#xD;
          -  Type 1, gestational or secondary diabetes.&#xD;
&#xD;
          -  History of diabetic ketoacidosis.&#xD;
&#xD;
          -  History of hypoglycemia unawareness.&#xD;
&#xD;
          -  Any medical contraindication for sustained and safe fasting.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Women of childbearing potential (WOCB) not protected by highly effective contraceptive&#xD;
             method(s) of birth control and/or who are unwilling or unable to be tested for&#xD;
             pregnancy.&#xD;
&#xD;
          -  Known hypersensitivity/intolerance to lixisenatide (Lyxumia) or any of its excipients.&#xD;
&#xD;
          -  All contraindications of the comparator and protocol mandated background therapies or&#xD;
             warning/precaution of use (when appropriate) as displayed in the respective National&#xD;
             Product Labeling.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 356005</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356002</name>
      <address>
        <city>Bangalore</city>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356015</name>
      <address>
        <city>Bangalore</city>
        <zip>560055</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356008</name>
      <address>
        <city>Bangalore</city>
        <zip>560060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356009</name>
      <address>
        <city>Hyderabad</city>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356018</name>
      <address>
        <city>Hyderabad</city>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356010</name>
      <address>
        <city>Hyderabad</city>
        <zip>500072</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356003</name>
      <address>
        <city>Hyderabad</city>
        <zip>500095</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356007</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356019</name>
      <address>
        <city>Madurai</city>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356014</name>
      <address>
        <city>Mumbai</city>
        <zip>400007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356022</name>
      <address>
        <city>Nagpur</city>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376001</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376002</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 414001</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792002</name>
      <address>
        <city>Zonguldak</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Israel</country>
    <country>Kuwait</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

